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ABSTRACT
The evaluation and management of severe asthma patients require collection of comprehensive 
information, which is often a challenge in a busy outpatient clinic. The Danish Severe Asthma Register 
(DSAR) was designed as an electronic patient record form that captures operational clinical data and 
provides a clinical overview of the severe asthma patient. DSAR is a nationwide register; all patients in 
Denmark who are treated with biologics for severe asthma are included, and data are as a minimum 
entered at start of biological treatment, after four and 12 months of treatment, and hereafter 
annually. Currently, there are data from 621 treatment courses with biologics included in DSAR, 
with 71% of patients treated with anti-IL-5 drugs and 29% with an anti-IgE drug. Patients enter Patient 
Reported Outcome Measures electronically on tablets when they arrive in the outpatient clinic and 
their answers are immediately available to the clinician during the consultation. Nurses and doctors 
enter clinical data into DSAR during the consultation. DSAR offers immediate access to well-presented 
longitudinal overview and automatically creates a journal output that can be copy-pasted into the 
hospital’s existing health record form. DSAR is also currently expanding with an app, to be used for 
monitoring of home-treatment. In addition to serving as an electronic patient record form, DSAR will 
also provide opportunities to monitor the real-life efficacy of biological treatment for severe asthma 
in Denmark, and it will be a valuable research platform that will aid in answering important research 
questions on severe asthma in the future.
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Introduction
In the European Respiratory Society (ERS) and 
American Thoracic Society (ATS) guidelines, severe 
asthma is defined as asthma, which requires treatment 
with high doses of inhaled corticosteroids in combina-
tion with a second controller (long-acting bronchodi-
lators, leukotriene-antagonists, xanthines) or treatment 
with systemic corticosteroids to prevent it from becom-
ing uncontrolled, or which remains uncontrolled 
despite this treatment [1]. Patients with seemingly 
severe asthma may also have other modifiable causes 
of poor asthma control, including lack of adherence to 
maintenance therapy, inadequate inhalation technique, 
exposure to asthma triggers, and a battery of co- 
morbidities [2–4]. Consequently, guidelines emphasize 
that a systematic assessment of patients with uncon-
trolled, and by that possibly severe, asthma by respira-
tory specialists is necessary to differentiate between 
true severe asthma and poor asthma control due to 
external factors. The systematic assessment is recom-
mended to include objective confirmation of the 
asthma diagnosis, phenotypic evaluation, identification 
of treatment barriers, and assessment of comorbidities 
and environmental exposures [1–3,5,6]. This is 
a comprehensive process that is time-consuming, not 
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always feasible in a busy clinical setting and is therefore 
may not always be performed; a diagnosis of severe 
asthma should only be given to patients that either are 
poorly controlled, or lose control when treatment is 
down-titrated, despite having optimal adherence, cor-
rect inhalation technique, removal of exposures and 
management of co-morbidities [1,3]. In two Danish 
studies examining patients seen by asthma specialists 
in outpatient clinics, it was found that among patients 
treated with high dose asthma medications – thus ful-
filling one of the characteristics of severe asthma – 
systematic assessment to confirm the severe asthma 
diagnoses was infrequently performed [7], and most 
patients could be classified as having ‘difficult-to-treat 
asthma’ rather than severe asthma [8]. These findings 
emphasize a substantial room for improvement in the 
systematic assessment and management of severe 
asthma patients.
Biological therapies that target specific inflammatory 
pathways have emerged as promising personalized 
medicines in the treatment of severe asthma [9,10]. 
Currently approved biologics include three anti- 
interleukin (IL)-5 drugs (mepolizumab, reslizumab, 
benralizumab), one anti-IgE (omalizumab) drug, and 
one anti-IL-4/IL-13 drug (dupilumab). Potential new 
targets for drug development are being tested, such as 
thymic stromal lymphopoietin (TLSP), and IL-33, and 
are at variable stages of development [9]. The approved 
drugs have shown to be very effective in reducing the 
risk of asthma exacerbations and with few side effects. 
However, they are expensive and there is substantial 
treatment response variability [11]. Appropriate selec-
tion of biologics for each individual patient requires 
knowledge about reliable biomarkers and precise char-
acterization of asthma phenotypes and this knowledge 
is therefore becoming increasingly important for spe-
cialists managing patients with severe asthma.
Taken together, a confirmation of the severe asthma 
diagnosis and the following best possible selection of 
treatment (personalized medicine) require collection 
and evaluation of comprehensive information. Hence, 
there is a need for systematic registration of severe 
asthma patients and of tools that can facilitate this 
process.
The Danish Severe Asthma Register (DSAR) is 
a new nationwide treatment register for severe asthma 
that has been developed with a threefold purpose: (1) 
An electronic journal to capture operational data and 
provide clinical overview, (2) to monitor the effect of 
biological treatment in Danish patients with severe 
asthma, and (3) to provide research possibilities.
In this paper we describe DSAR and its organiza-
tional structure, the patient population, the variables 
collected, the time points of data collection, the model 
for data entry and the expected benefits of DSAR. We 
also provide a brief characterization of the study popu-
lation, as well as discuss some strengths and limitations 
of the collected data.
Cohort description
Study population
All Danish patients commenced on a biological asthma 
therapy must be entered into DSAR, with a baseline 
visit, prior to commencing the treatment. Outpatient 
clinics may also choose optionally to include all 
patients with severe asthma according to ERS/ATS 
guidelines [1], but this is not a formal requirement.
Organizational structure
DSAR was initiated by the Danish Respiratory Society 
in 2017 and is governed by an independent steering 
committee, with representatives from each of the par-
ticipating clinical departments. Experience from other 
fields has shown that the long-term sustainability of 
a clinical registry is dependent on a culture change at 
the every-day clinical practical level in order for clin-
icians to gain value from their participation in the 
registry [12]. Therefore, it was deemed important to 
have representatives from all departments that admin-
ister biological drugs to treat severe asthma in 
Denmark to secure support for the register locally. 
Originally, this included eight respiratory departments, 
later, this has grown to include ten departments from 
all regions of Denmark (see Figure 1). It is the Danish 
National Board of Health that determines which 
departments are allowed to administer biological treat-
ment for severe asthma, and it is a specialist task to 
prescribe the treatment and secure follow-up according 
to guidelines.
The steering committee is responsible for handling 
financial, regulatory, and scientific matters of DSAR. 
The daily administration is based at Bispebjerg 
Hospital in Copenhagen staffed with an academic 
secretary and a project coordinator, led by the chair 
of the steering committee.
DSAR is sponsored by the Danish Respiratory 
Society as well as pharmaceutical companies (Glaxo 
Smith Kline, Novartis, AstraZeneca, Teva, and 
Sanofi). The sponsors have no influence on the man-
agement of the registry, or the results that will be 
published based on data from the registry. Each com-
pany has signed a contract with the registry that has 
2 S. HANSEN ET AL.
been approved by the legal department in the Capital 
Region.
IT solution
DSAR is a customized electronic database that is 
accessed at www.dsar.dk. Health care professionals 
have a personal log-in and their activity is logged. 
DSAR is placed on a private virtual service running 
Ubuntu-Linux with separation between frontend server 
(visible from the Internet) and backend-server where 
the data are stored. The DSAR system consists of two 
interconnected systems for health care professionals 
and patients. The system is developed and maintained 
by ZiteLab ApS with use of an Opensource IT-platform 
called Plone (plone.org) known for its outstanding 
security-record.
ZiteLab has implemented similar systems in several 
medical fields using the same IT-platform including 
DANBIO, which is a large nationwide registry includ-
ing approximately 60.000 patients with rheumatologic 
diseases. The use of research data from the DANBIO 
registry has led to more than 60 peer-reviewed articles 
[13–15].
Variables collected
Variables included in DSAR are coordinated with the 
variables collected in the two existing international 
severe asthma databases, which are currently being 
set up: The International Severe Asthma Register 
(ISAR) [16] and the pan-European database under 
ERS, the Severe Heterogenous Asthma Research 
Collaboration, Patient-centered (SHARP) ERS 
Clinical Research Collaboration [17]. This will provide 
opportunities for comparing data, but also for inte-
grating data for international research projects and 
publications. Furthermore, DSAR includes additional 
variables decided upon in the Nordic Severe Asthma 
Network as well as variables decided by the DSAR 
steering committee to ensure that all needed clinical 
information was collected to support the use of DSAR 
as a decision-supporting patient record form.
The content of DSAR is presented in Table 1. A full 
list of the variables collected in DSAR can be seen in 
Appendix 1.
Data entry
Data are entered by patients, nurses, and doctors. The 
collection of real-life data in a busy clinical setting is 
associated with some logistic challenges. The data 
entry performed by health care professionals must be 
feasible and possible to integrate in normal routine 
care to secure that only very limited extra time is 
spent on the data entry [18]. When designing DSAR, 
a key priority has been to develop a user-friendly web- 
based solution that can be used ‘real-time’ during the 
consultation with no post-registration needed. 
Importantly, this solution furthermore ensures that 
summaries of the collected data are immediately avail-
able to the clinicians, providing an overview of the 
Figure 1. Overview of hospitals in Denmark administering biological treatment for severe asthma.
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patient’s situation and response to treatment. This 
overview can also be used in real-time to discuss 
treatment decisions and evaluations with the patient. 
The clinical overview is described in further detail 
below.
Patients
Patients are asked to provide their input by answering 
electronic Patient Reported Outcome Measures 
(PROMs) on tablets handed out upon registration in 
the outpatient clinics. The PROMs have been selected 
by the steering committee and include internationally 
approved questionnaires to assess asthma control, qual-
ity of life, and identification and control of co- 
morbidities. For a list of the PROMs currently collected 
in DSAR, see Table 1. The validity of electronic ques-
tionnaires compared to paper forms has not yet been 
investigated in this patient group, but experience from 
other medical fields has shown good performance of 
the electronic questionnaires [19]. After patients have 
completed the PROMs, their answers can immediately 
be imported into DSAR and made available for the 
doctors’ evaluation during the consultation.
Professionals
Nurses and doctors enter clinical information into 
DSAR during the consultation with direct data entry 
into the electronic journal. The local departments 
decide who is responsible for entering which variables 
depending on the local organization and staff respon-
sibilities. Variables are collected in a standardized for-
mat, using tick boxes or free text fields. For variables 
entered as values, there is an automatic data range 
validation implemented in the system with pre- 
defined meaningful ranges for each variable (if applic-
able). If an unrealistic value is entered, a pop-up warn-
ing appears.
Follow-up visits
Patients treated with biologics are followed-up accord-
ing to predefined time points to secure comparable 
information from all patients. Figure 2 provides an 
overview of the follow-up and the visit types in 
DSAR. The extent of data entry varies according to 
these visits.
Patients are included in DSAR when biological 
treatment is initiated. Information from the systematic 
assessment that precedes the decision to start the 
patient in biological treatment is entered into DSAR 
as a ‘baseline visit’. The specific indications for starting 
treatment are recorded as well as the type of drug and 
start date. Currently prescribed medication for each 
individual patient is registered.
A ‘four months control visits’ follows the baseline 
visit and includes the first mandatory assessment of the 
treatment effect. At this visit, symptom control is 
assessed by the means of the Asthma Control 
Questionnaire (ACQ), the number of exacerbations 
since start of treatment are registered, as well as 
changes in medication (OCS use).
After one year of treatment, an ‘annual control visit’ is 
completed with a thorough assessment of symptom con-
trol, medication status, objective tests, allergy tests, inflam-
matory markers, treatment barriers, exposures and 
triggers, co-morbidities and treatment plan. Changes in 
medication are registered as well as information on poten-
tial severe side effects from biological treatment.
After the first year of treatment, patients are fol-
lowed longitudinally with at least one annual doctor 
Table 1. Overview of core variables collected in the Danish 
Severe Asthma Register.
Type of variable Name of variable
Sociodemographic factors Age, sex, height, weight, ethnicity
Medical history Age at asthma onset, allergy, atopic eczema 
diagnosis, intubation history, treatment 
with bronchial thermoplastic, current 
status
Medicine Current treatment (start date, dose, 
frequency, interval), information entered 
for all types of asthma medication
Safety Side effects, malignancy, anaphylaxis, 
severe infections
Symptom control Exacerbations, admission, A&E visits in past 
12 months
Objective tests Lung function 
Diagnostic tests (reversibility test with 
SABA, mannitol, methacholine, exercise 
test, EHV, PEF, OCS) 
Radiology 
Dexa scanning
Allergy tests Serum specific IgE test 
Skin prick test





Expositions Smoking history 
Occupational status
Co-morbiditities Allergic rhinitis, eczema, chronic 
rhinosinusitis, nasal polyps, aspirin 
intolerance, allergic bronchopulmonary 
aspergillosis, bronchiectasis, chronic 
obstructive pulmonary disorder, EGPA, 
eosinophil pneumonia, dysfunctional 
breathing, vocal cord dysfunction, 
gastroesophageal reflux disease, 
cardiovascular disease, anxiety and 
depression, obstructive sleep apnea 
syndrome.
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visit. ‘Extra doctor visits’ can be entered as needed if 
departments wish to use DSAR for all doctor visits. If 
a patient switches to another biological drug, a new 
baseline visit should be entered, followed by a 4 months 
control, and an annual control and so on.
Administration of biological treatment can also be 
recorded at each injection, and if clinical measures are 
obtained, these can also be recorded. This registration 
is voluntary but allows electronic registration of treat-
ment administration which has obvious advantages 
compared to registration on paper forms.
App for home treatment
DSAR’s IT provider has developed an app that can be 
downloaded on smartphones that eventually will 
allow patients to complete PROMs from home or in 
connection with home treatment that are expected to 
grow in numbers in the coming years. Patients can 
log in from home on their smartphones or tablets and 
answer questionnaires about their self-reported health 
and symptom control. The app will also enable com-
pletion of questionnaires at home prior to visiting the 
outpatient clinic. The app is currently being 
expanded to allow for monitoring of home treat-
ments: This will include reminders to the patients to 
take their medications, registration of dates of 
administration and side effects, as well as an action 
plan in case of exacerbations. The app is expected to 
be ready for clinical use in 2020.
The app has been approved by authorities in the 
Capital Region of Denmark overseeing IT-technical 
and legal aspects of General Data Protection 
Regulation (GDPR).
The contribution of DSAR to severe asthma 
management, monitoring of treatment efficacy, 
and research
DSAR is unique in that it will both serve as an impor-
tant real-life decision-making tool in the clinic, it will 
provide a solid foundation for nationwide monitoring 
of treatment efficacy of biologics for severe asthma, and 
it will serve as an important research database. The 
main benefits of DSAR are summarized in Figure 3 
and described in detail below.
DSAR purpose 1: clinical overview
DSAR will provide health care providers with a well- 
presented longitudinal electronic patient record of the 
severe asthma patient treated with biologics that ulti-
mately has the potential to improve outcome in the 
individual patient.
Figure 2. Overview of DSAR visits and collected data. One model for data entry with patients completing PROMs and nurses and 
doctors responsible for part of the clinical data entry.
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The clinical overview is designed into three main 
outputs: a patient summary table, a biological treat-
ment table, and a patient scoreboard (Figure 4).
The patient summary includes demographic and 
phenotypic characteristics of the patient, information 
about which diagnostic tests confirmed the asthma 
diagnosis, the presence of allergy, values of the high-
est ever recorded FeNO, FEV1 and blood eosinophils, 
and smoking history. The values are directly 
extracted from the database and are automatically 
updated when new values that exceed previous are 
entered. The biological treatment table includes type 
of biologics, start date, and number of doses admi-
nistered. The main part of the patient overview is 
comprised of the patient scoreboard that presents 
longitudinal information about the disease course. 
The scoreboard is a table with each column corre-
sponding to a visit on a given date in the outpatient 
clinic. Displayed variables include information on 
ACQ, exacerbations, medication status including 
OCS use, lung function, inflammatory markers, pre-
sence of co-morbidities, smoking status, and com-
ments to treatment plan. FEV1% of predicted value 
is auto-calculated based on the entered value of FEV1 
held together with reference values for lung function 
and core data about the patient, including height, 
ethnicity, and sex.
Much of the information in the patient scoreboard is 
displayed as collapsible content that can further be 
expanded by simple clicks. Additional information 
can be obtained by clicking on a value that opens 
a pop-up window with more information about 
a given variable. This function ensures that the score-
board is simple and provides a quick overview without 
too much information but at the same time it can be 
expanded to show detailed information if needed.
DSAR will not initially be linked directly with the 
hospital’s electronic patient records and therefore some 
double data-entry is needed. Therefore, an important 
functionality in DSAR is the automated clinical sum-
mary that can be generated and copy-pasted directly 
into the hospital’s electronic patient record. When 
a visit is completed in DSAR, the automatic clinical 
summary extracts values from the entered variables 
and presents the output in a structured text that fulfills 
the standard for a sufficient clinical output. This has 
minimized the amount of double data entry.
DSAR purpose 2: monitoring of treatment effects
With the introduction of DSAR, there will be 
a possibility to monitor the treatment of severe 
asthma with biologics in Denmark on several levels. 
DSAR will allow systematic evaluation on a national 
level of the number of patients treated and the use 
of different types of treatment. Biological treatment 
for severe allergic asthma has been available for 
several years, but the spread and follow-up geogra-
phically seem to be heterogeneous in Denmark. 
New anti-IL-5 treatments have been approved and 
in the upcoming years additional biological treat-
ments will be available. Recently, notification duty 
has become mandatory in Denmark when it comes 
to the use of IL-5 biologics [20]. DSAR will there-
fore enable departments to fulfill this juridical 
requirement.
Health care providers will have an overview of all 
patients treated in their department with biologics 
and some summary statistics such as number of 
patients treated stratified by type of treatment, and 
they will be able to compare their patients with 
national data.
Purpose 2: Monitoring of treatment 
effects
∙ Overview of paents treated with 
biologics on a local (department) level
∙ Comparisons on naonal levels
→ Improvements in quality of treatment
Purpose 1: Electronic patient 
record form
∙ Structured overview 
of the individual paent
∙ Supports clinical decision-
making
→ Improvement of outcome in the 
individual paent
Purpose 3: Research
∙ Paents provide informed consent
∙ Data available for severe asthma research





Figure 3. Main purposes of DSAR and the expected benefits.
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DSAR purpose 3: a research database
Data from clinical registries provide an ideal platform 
for medical research and enable studies on real-life 
efficacy [18]. DSAR is therefore expected to provide 

































Paent is on a biologic drug
Paent scoreboard
19 Apr 2018 14 Aug 2018 5 May 2019
Journal note Journal note Journal note
Type of visit Baseline 4 months Annual control
Asthma control
ACQ 2,4 2,2 0,57
AQLQ 15 10 10
WPAI 20 15 10








ICS Bud. Eq. dos 1600 1600 1600
SABA Bric. 0,5 mg pn Bric. 0,5 mg pn Bric. 0,5 mg pn
Monteleu. Sing. 10 mg/d Sing. 10 mg/d Sing. 10 mg/d
OCS Predn. 10 mg/d Predn. 7,5 mg/d
Bio Nucala Nucala Nucala
Lung funcon
FEV1 (l) 3,2 3,4 3,5
FEV1 % 83 85 87
FEV1/FVC 0,78 0,80 0,82
Add. measures Yes No No
Infl. Markers
FeNO 41 52 38
B-eos 0,78 0,20 0,25
Total IgE 552
Treatm. barriers
Adh. No Not rep. No
Inh. Techni. Yes Yes Yes
Exposures
Smoking Ex Ex Ex
Co-morbidies
Co-morb Yes Yes Yes
Ques!onnaires Show Show Show
Comments
Treatm. plan Yes Yes Yes
Year 1 Date of adm. Batch no. ACQ FeNO …
Dose 1 19 Apr 2018 H95r 2,4 41
Dose 2 23 May 2018 Lu8k
Dose 3 18 June 2018 6e5g







On average in the past week, how o"en were 
you woken up by your asthma during the 
night?
0
On average in the past week, how bad were 
your asthma symptoms when you woke up in 
the morning?
0
In general, during the past week, how limited 
were you in your ac!vi!es because of your 
asthma?
1
In general, during the past week, how much 
shortness of breath did you experience 
because of your asthma? 
1
In general, during the past week, how much 
!me did you wheeze?
1
On average, during the past week, how many 
puffs/inhala!ons of short-ac!ng broncodilator 





Generates clinical summary from the visit that can be 
copy-pasted into the hospital’s health record form
First dose 19 APR 2018
Exp. 4 months control 19 AUG 2018
Exp. annual control 19 APR 2019
Nucala
Figure 4. Clinical overview in DSAR: patient summary, biologic drug table, and scoreboard. Information is expanded when clicking 
on the hyperlinks.
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The use of data from DSAR for research purposes 
relies on patients providing informed consent. Consent 
can then be given on the tablets, with a signature on 
the screen. A clear distinction between DSAR as an 
electronic journal and a research database is made; 
informed consent is only provided with respect to 
research. The informed consent is automatically 
requested annually, in accordance with Danish laws.
Researchers can apply for access to data from DSAR 
by contacting the steering committee which approves 
applications. Projects must be approved by the relevant 
authorities before approval from the steering commit-
tee can be sought and anonymous data ultimately 
delivered to the researchers.
There will be opportunities to link data from DSAR 
with data from many Danish nationwide registers such 
as the Danish National Patient Register (hospital 
admissions, therapies, diagnoses) and the Registry of 
Medicinal Product Statistics (prescriptions redeemed in 
Danish pharmacies) or the Danish General Health 
Database (education, socioeconomic, demographics). 
Data linkage is conducted through the personal identi-
fication number given to all citizens in Denmark and 
enables coupling of information on an individual 
level [21].
Data reports
Annually, a report presenting information on 
a national level will be publicly available on the home-
page www.dsar.dk. These reports will include key data 
on characteristics of severe asthma patients treated 
with biological and the efficacy of treatment. Regular 
reports will be created based on national DSAR data to 
the steering committee to secure high data quality and 
allow monitoring of the performance of each depart-
ment involved in DSAR.
Collaboration
The Danish Severe Asthma Register collaborates with 
the International Severe Asthma Registry, the Severe 
Heterogeneous Asthma Research collaboration, 
Patient-centred (SHARP), and the Nordic Severe 
Asthma Network. It is the goal of DSAR that with the 
necessary permission processes in place, collaborators 
can get access to data for research. More information is 
available at www.dsar.dk.
Ethics and approvals
Approval to DSAR was sought simultaneously as the 
European Union GDPR was implemented, which 
resulted in some challenges in getting the sufficient 
approvals. DSAR has been approved as a treatment 
database by the Danish Data Protection Agency mean-
ing that it can be used as a patient record form in the 
department without seeking direct approval from the 
patients regarding the use for clinical purposes 
(approval number VD-2018-116). A separate approval 
for research has furthermore been obtained, and this 
approval is conditioned on patients providing 
informed consent (approval number VD-2018-31). 
Data processing agreements are made between the 
data controller and the data processor that sets out 
the rights and obligations that apply to data processor’s 
handling of data on behalf of the data controller. The 
agreements comply with the regulations by the 
European Parliament.
Results
DSAR currently includes data from 621 biological 
treatment courses. Of these, 440 are treatments with 
anti-IL 5 drugs (71%), and 181 (29%) are treatment 
with the anti-IgE drug, omalizumab. The anti-IL 5 
drugs used are mepolizumab (n = 311), benralizumab 
(n = 87), and reslizumab (n = 42).
To date, 311 patients have provided informed consent 
that their data can be used for research purposes. Baseline 
characteristics of these patients are presented in Table 2.
The average patient starting on biologics in 
Denmark is 54 years (interquartile range (IQR): 18) 
old with adult onset asthma (90%) and is most often 
never-smoker (56%). There is almost an equal amount 
of men and women starting on biologic treatment (48% 
women). With respect to the demographic character-
istics, there are few differences between patients start-
ing on the four types of biologics drugs. However, 
patients starting on omalizumab are younger when 
they start treatment (46 years, IQR: 18), more often 
female (61%), and a higher proportion of patients had 
onset of asthma in childhood or adolescence (14%) 
compared to patients starting on anti-IL-5 
drugs (0–10%).
At start of treatment, patients starting on biologics 
have experienced a median number of 3 (IQR: 4) 
exacerbations in the previous year. The median num-
ber of exacerbations varies between the four different 
types of drugs with numbers of 3 (IQR: 3), 1 (IQR: 2), 
3 (IQR: 6), and 6 (IQR: 4) for mepolizumab, omali-
zumab, benralizumab, and reslizumab, respectively. 
The average patient has a FEV1 of 2.4 (1.7–3.0) 
l with few differences in lung function measures 
between the patients starting on the four biologic 
drugs. Patients starting on anti-IL5 drugs have on 
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average higher FeNO and blood eosinophil counts 
compared to patients starting on omalizumab, 
whereas patients starting on omalizumab and benra-
lizumab have higher total IgE compared to patients 
starting on mepolizumab and reslizumab.
Discussion
DSAR is a nationwide registry and includes all patients 
in Denmark with severe asthma who are treated with 
biologics. To our knowledge, it is the first severe 
asthma register to include all patients in an entire 
country. Currently, there are data from 621 biologic 
treatment courses included in DSAR.
Although efforts have been made to make DSAR 
easy to use, the implementation process has revealed 
that it is time consuming for clinicians to get used to 
a new patient record form in a busy outpatient clinic. 
Doctors and nurses have been taught how to use the 
system during training sessions, but real-life use of 
DSAR has been challenging for some departments 
due to heavy work load. Post-registration of patients 
has therefore been necessary, which is not how DSAR 
is intended to be used and which has added a data 
entry burden on the clinician. In line with this, we have 
observed that departments with many clinicians over-
seeing few patients on biological treatments have per-
ceived DSAR more difficult to use due to long time 
gaps between the use of the system for the individual 
doctor and nurse. In contrast, departments organized 
around fewer nurses and doctors overseeing many 
patients on biologics have shown a stronger commit-
ment to use the system and have built up routines 
faster in the clinic that has allowed for real-time use 
of DSAR. In the initial phase, prioritizing dedicated 
time along with frequent use of the system is therefore 
warranted.
Unfortunately, some double data entry is inevitable, 
since DSAR is not currently integrated with the exist-
ing hospital records. Hospitals in Denmark use differ-
ent electronic record forms and therefore it has been 
impossible to make data integrations between these 
systems and DSAR. However, prescription medications 
are registered in the same nationwide system, the 
Shared Medication Record, and there are currently 
efforts being made to integrate DSAR with this central 
database, which would have obvious advantages. The 
double data entry issue has, however, been minimized 
by the possibility of creating a journal summary in 
DSAR that can be copy-pasted into the hospital record. 
Feedback from users has indicated that this is a helpful 
feature of DSAR.
Although the registry includes all patients on biolo-
gical treatment for severe asthma in Denmark, some 
patients were already on treatment before DSAR was 
initiated. A retrospective data entry was completed for 
existing users of biologics starting from 2015 and 
onwards to include all patients being treated with anti- 
IL-5 biologics. However, for patients treated with oma-
lizumab which has been on the market for almost two 
Table 2. Baseline characteristics of patients with severe asthma treated with biologics in the Danish Severe Asthma Register. Only 
patients who have provided informed consent that their data can be used for research purposes are included.
All Mepolizumab Omalizumab Benralizumab Reslizumab
N = 311 N = 172 N = 71 N = 45 N = 17
Demographic characteristics
Age at start of biologic treatment (years) 54 (45–63) 56 (48–65) 46 (37–55) 57 (48–63) 56 (47–63)
Sex (% women) 48 46 61 38 41
Body mass index (kg/m2) 27 (24–30) 26 (24–30) 28 (24–30) 27 (24–30) 27 (24–30)
Age at asthma start (years) 38 (18–52) 35 (20–51) 24 (5–39) 41 (26–54) 56 (42–62)
Age < 18 years (%) 10 10 14 10 0
Age 18–40 (%) 38 41 46 24 33
Age ≥ 40 (%) 52 49 41 67 67
Current smoker (%) 6 4 9 8 6
Previous smoker (%) 38 49 31 32 56
Never smoker (%) 56 56 60 60 38
Smoking packyears (years) 17 (8–30) 15 (8–22) 20 (18–35) 19 (8–29) 33 (30–46)
Asthma control
No. of exacerbations in the past 12 months 3 (1–5) 3 (2–5) 1 (0–2) 3 (2–8) 6 (3–7)
Asthma control questionnaire score 2.71 (1.86–3.38) 2.71 (1.86–3.35) 2.29 (0.50–2.71) 3.14 (2.60–4.14) 2.80 (1.58–3.36)
Asthma control test score 13 (8–19) 13 (9–18) 13 (8–14) 18 (14–21) 8 (8–14)
Clinical characteristics
FEV1 (l) 2.4 (1.7–3.0) 2.2 (1.7–2.9) 2.5 (1.9–2.4) 2.5 (1.9–2.8) 2.8 (2.6–3.2)
FEV1% of predicted value 71 (55–87) 72 (54–86) 70 (61–86) 71 (56–84) 83 (63–100)
FEV1/FVC ratio 0.69 (0.57–0.76) 0.68 (0.56–0.75) 0.72 (0.59–0.78) 0.68 (0.63–0.72) 0.69 (0.62–0.74)
FeNO (ppb) 29 (19–60) 32 (18–55) 16 (11–31) 40 (20–83) 27 (22–60)
Blood eosinophil count (109/l) 0.30 (0.17–0.48) 0.35 (0.17–0.54) 0.16 (0.08–0.27) 0.20 (0.1–0.49) 0.32 (0.26, 0.50)
Total IgE (kUA/l) 196 (162–693) 135 (59, 331) 372 (163–912) 471 (212–785) 88 (56–124)
Values are n, % or median (p25-p75) 
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decades, it was not feasible to make retrospective jour-
nal reviews going all the way back to start of treatment, 
which has resulted in some incomplete baseline data. 
For other omalizumab patients, ‘baseline’ visits have 
been entered with clinical values from 2015 that 
could have been obtained after several years of treat-
ment. This may explain why patients starting on oma-
lizumab experience fewer exacerbations in the year 
leading up to treatment compared to the number of 
exacerbations in patients starting on anti-IL-5 treat-
ment. The retrospective data, and in particular for 
omalizumab patients treated for a long duration may 
therefore be of varying quality.
Some patients may switch biologics, for instance if 
there is a lack of sufficient treatment response, and in 
DSAR, a new baseline visit should be created at time of 
switching to the new drug. These new baseline visits 
include clinical values that are not independent of the 
previous treatment. This could perhaps explain the 
high number of exacerbations in patients starting on 
reslizumab which is often not the first choice of treat-
ment with anti-IL-5 biologics. On the other hand, 
switching biologics to benralizumab may also be done 
in patients who are well controlled at time of switching, 
since benralizumab is administered every 8 weeks com-
pared to every 4 weeks for the other anti-IL-5 drugs. 
This may explain why blood eosinophils in patients 
starting on benralizumab are lower than that of 
patients starting on mepolizumab and reslizumab. 
These above examples clearly indicate that careful con-
siderations of the potential pitfalls of real-life data are 
important to keep in mind when using data from 
DSAR. Analyses of bionaive patients may be one way 
of tackling these specific issues.
Currently, eight departments are using DSAR in the 
clinic, and two more departments are set to start using 
the system in 2020. The registration of patients has so 
far solely been done for patients on biological treat-
ment, and data from DSAR are therefore currently 
restricted to this specific severe asthma patient popula-
tion rather than patients with severe asthma in general. 
Future use of DSAR may include registration of all 
severe asthma patients, which would allow for interest-
ing comparisons between patients with severe asthma 
treated with and without biologics.
Conclusion
DSAR is a new nationwide treatment- and research 
register over patients with severe asthma treated with 
biologics in Denmark. DSAR serves as an electronic 
patient record form on the individual level and pro-
vides real-life data to the clinician to improve decision 
making through several well-presented outputs. This 
feature ensures that value is being provided back to 
the clinician, rather than being a ‘one-way’ data entry 
into a registry. DSAR also provides opportunities to 
monitor treatment effects nationally, and it will be 
a valuable research platform that will aid in answering 
important research questions on severe asthma in the 
future.
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Patient details Social security number X
Name X
Sex autocalculated form social security number X
Age autocalculated from social security number X
Ethnicity X
Height X
Weight X (X) (X)
BMI autopopulated from height and weight X
Medical 
history




Invasive ventilation frequency ever X
Invasive ventilation frequency in past 12 months X
Bronchial thermoplasty frequency ever X
Bronchial thermoplasty frequency in past 12 months X
Symptom 
control
Exacerbations in the past 12 months X X
A&E attendances for asthma in the past 12 months X X
Hospital admissions for asthma in the past 12 months X X
Exacerbations since last time X
Main current complaint (free text) X X X
Objective 
tests
Spirometry X X X
Date of spirometry X X X
Pre-bronchodilator FEV1 X X X
Pre-bronchodilator FVC X X X
FEV1% (autocalculated from FEV1, height, sex, ethnicity) X X X
FEV1/FVC ratio (autocalculated from FEV1 and FVC) X X X
Reversibiltiy to SABA X X
If yes, Post-bronchodilator FEV1 X X
If yes, Post-bronchodilator FVC X X
Metacholine test X X
If yes, PD20 result X X
Mannitol test X X
If yes, PD15 result X X
Exercise test X X
If yes, % increase in FEV1 X X
Eucapnic voluntary hyperventilation tes X X
If yes, % decrease in FEV1 X X
PEF monitoring X X
If yes, % reversibility X X
Reversibility to prednisone X X
If yes, % increase in FEV1 X X
Was CT scan (chest) performed X X
If yes, date and result (normal, abnormal) X X
Was bone densitometry (DEXA) performed X X
If yes, date of dexa scan X X
Allergy tests Serum specific IgE X X
If yes, date of specific IgE test X X
If yes, specification of serum allergen test (CAP, ELISA, RAST) positive allergens X X
Skin prick test X X
If yes, date of skin prick test X X
If yes, specification of SPT positive perennial allergens X X
Inflammatory 
markers
Blood eosinophil count X X X
If yes, current no of b-eos X X X
Highest no of b-eos in the past 12 months X X
Sputum eosinophil count X X
If yes, highest no of sputum eos in the past 12 months X X
Current IgE count X X
If yes, result X X
Exhaled nitric oxide X X X
If yes, result X X X
Treatment 
barriers
Evidence of poor adherence X X X
Inhaler technique checked X X X
Adequate inhaler technique X X X
(Continued )
Appendix 1. DSAR full variable list and time points of collections










Exposures Current smoking status X X
Mean no of cigs smoked per day (present or past) X X
Number of smoking years X X
Pack years (autocalculated) X X
Years since patient smoked last time X X
Current occupation of the patient X X
Medications For all types of drugs: ICS, ICS/LABA, ICS/LABA/LAMA, SABA, SAMA, SABA/SAMA, LAMA, LABA, LABA/ 
LAMA, leukotriene receptor antagonists, OCS, macrolides, teophyllins, the following variables are 
registered:
X X X
Drug start date X X X
Drug name X X X
Strenght X X X
Frequency X X X
Number of puffs (for inhalers) X X X
Budesonid equivalent dose (autocalculated) X X X
Every day or PN medication X X X
And if relevant, drug stop date, drug stop reason X X X
For biologics the following variables should be registered: X X X
Strenght X X X
Frequency X X X
Reason for commencing drug X X X
And if relevant, drug stop date, drug stop reason X X X
Side effects Have any of the following side effects occurred in the past 12 months? No side effects, severe 
infections, new onset malignancies, anaphylaxis, others (specify)
X
If yes, date of side effect, specific type of side effect, outcome of side effect X
Comorbidity Allergic rhinitis (never, past, current) X X
Eczema (never, past, current) X X
Atopic disease (autopopulated if indicated current for allergic rhinits or eczema) X X
Chronic rhinosinusitis (never, past, current) X X
Nasal polyps (never, past, current) X X
Aspirin sensitivity (never, past, current) X X
ABPA (never, past, current) X X
Bronchiectasis (never, past, current) X X
Chronic obstructive pulmonary disease (COPD) (never, past, current) X X
EGPA (never, past, current) X X
Eosinophilic pneumonia (never, past, current) X X
Dysfunctional breathing (never, past, current) X X
VCD (ILO/EILO)(never, past, current) X X
Gastroesophageal reflux disease (GERD) (never, past, current) X X
Cardiovascular disease (never, past, current) X X
DM (never, past, current) X X
Psychiatric disease (never, past, current) X X
Obstructive sleep apnea (OSA) (never, past, current) X X
Plan What is the current clinical management plan? X X
Can the patient be contacted for research purposes? X X X
Is the patient currently participating in research projects? X X
Effect of biological treatment (free text) X X
Conclusion and treatment plan X X x
PROMs ACQ X X X
AQLQ X X X
WPAI X X X
SNOT-22 X X
Epworth Sleepiness Scale X X
Nijmegen X X
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